The effect of curcumin in the treatment of patients with acute myocardial infarction

Evaluation of the effect of curcumin on serum levels of inflammatory markers in patients with acute myocardial infarction

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017010922381N3

Enrollment

Registered

2017-02-08

Start date

2017-02-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction. myocardial infarction specified as acute or with a stated duration of 4 weeks (28 days) or less from onset

Interventions

Intervention 1: Intervention group: Curcumin, 500 mg capsules? single dose per day for 2 months, the chemical formula: C21H2O6. Intervention 2: Control group: placebo, starch, 500 mg capsules? single

Treatment - Drugs

Placebo

Intervention group: Curcumin, 500 mg capsules? single dose per day for 2 months, the chemical formula: C21H2O6

Control group: placebo, starch, 500 mg capsules? single dose per day for 2 months

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosed Acute MI based on clinical signs, electrocardiogram and serum markers; older than 18 years; maximum age of 75 years; written consent form. Exclusion criteria: Diabetes; renal failure; liver failure; immunosuppressive drugs; pentoxifylline; cilostazol consumption; inflammatory diseases; sensitivity of curcumin (turmeric); leukocytosis with a left Schiff; the use of glucosamine. Barberry juice consumption; malabsorption disorders; history of clotting problems; history of consumption anticoagulant therapy; patients with surgical indications.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
MCP-1. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-2. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-6. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-8. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-1a. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-1ß. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;VEGF. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;TNFa. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;EGF. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;INF-?. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-4. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-10. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;Hs-CRP. Timepoint: Before intervention and two months after intervention. Method of measurement: Mg / dl using blood tests.;Homosysteine. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.	—

Measure

Time frame

MCP-1. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-2. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-6. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-8. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-1a. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-1ß. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;VEGF. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;TNFa. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;EGF. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;INF-?. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-4. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;IL-10. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.;Hs-CRP. Timepoint: Before intervention and two months after intervention. Method of measurement: Mg / dl using blood tests.;Homosysteine. Timepoint: Before intervention and two months after intervention. Method of measurement: pg / ml using blood tests.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamaneh Tabaee

Neyshabur University of Medical Sciences

tabaees79@yahoo.com+98 514334401112

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026